The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2011 ASCO Annual Meeting

Wednesday, May 18, 2011

ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2011 ASCO Annual Meeting16:35 EDT Wednesday, May 18, 2011 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new data on ponatinib, its investigational pan-BCR-ABL inhibitor, and ridaforolimus, an investigational mTOR inhibitor discovered by ARIAD and now being developed by Merck, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3 to 7, 2011. Comprehensive data from the global Phase 3 SUCCEED trial of oral ridaforolimus in patients with metastatic soft-tissue and bone sarcomas who have had a favorable response to cytotoxic chemotherapy will be presented in an oral session on Monday, June 6. The presentation will include data on the trial's primary and secondary endpoints and analyses from predefined patient sub-groups. In addition, clinical data on ponatinib in patients with FLT3-positive acute myeloid leukemia will be presented in a poster session on Friday, June 3. The schedule and meeting location for the sessions, together with the abstract information and details on the investor briefing, are listed below: Ridaforolimus Title: Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG (The NCIC Clinical Trials Group) Date & Time: Friday, June 3, 2:00 PM – 6:00 PM CT (Poster) Abstract: #5013 Presenter: Helen MacKay, M.D. (Princess Margaret Hospital, Toronto, ON, Canada) Location: E450a Title: Results of the Phase 3, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT) Date & Time: Monday, June 6, 4:30 PM – 4:45 PM CT (Oral presentation) Abstract: #10005 Presenter: Sant Chawla, M.D. (University of California Los Angeles-Santa Monica Hospital) Location: E354a Title: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer. Date & Time: Monday, June 6, 8:00 AM – 12:00 PM CT (Poster) Abstract: #TPS110 Presenter: Scot Ebbinghaus, M.D. (Merck, Whitehouse Station, NJ) Location: Hall A Title: A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma Date & Time: Saturday, June 4, 5:00 PM – 5:15 PM CT (Oral presentation) Abstract: #5009 Presenter: Amit Oza, M.D. (Princess Margaret Hospital, Toronto, ON, Canada) Location: E354a Ponatinib Title: Ponatinib in patients with acute myeloid leukemia (AML): preliminary findings from a Phase 1 study in hematologic malignancies Date & Time: Friday, June 3, 2:00 PM – 6:00 PM CT (Poster discussion session) Abstract: #6518 Presenter: Moshe Talpaz, M.D. (University of Michigan, Ann Arbor, MI) Location: E450b Investor Briefing and Webcast: ARIAD will hold an investor briefing on Monday, June 6, from 5:45-6:45 p.m. CT at the Renaissance Blackstone Hotel to discuss the comprehensive data from the Phase 3 SUCCEED trial. Sant Chawla, M.D., Director of Medical Oncology at the University of California Los Angeles-Santa Monica Hospital, will join members of ARIAD's management team for the briefing. This meeting will be webcast live and can be accessed by visiting the investor relations section of ARIAD's website at: http://investor.ariad.comor by dialing 800-265-0241 (domestic) or 617-847-8704 (international) five minutes prior to the start time and providing the pass code 91808133. A replay of this investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived for three weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit http://www.ariad.com. ARIAD Pharmaceuticals, Inc.For InvestorsMaria E. Cantor, 617-621-2208orFor MediaLiza Heapes, 617-621-2315